[go: up one dir, main page]

MX2019006721A - TREATMENT FOR PRIMARY BILE CHOLANGITIS. - Google Patents

TREATMENT FOR PRIMARY BILE CHOLANGITIS.

Info

Publication number
MX2019006721A
MX2019006721A MX2019006721A MX2019006721A MX2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A
Authority
MX
Mexico
Prior art keywords
treatment
primary bile
cholangitis
pbc
bile cholangitis
Prior art date
Application number
MX2019006721A
Other languages
Spanish (es)
Other versions
MX382765B (en
Inventor
Jain Mukul
Philip Binu
Patel Pankaj
Giri Suresh
V Parmar Deven
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2019006721A publication Critical patent/MX2019006721A/en
Publication of MX382765B publication Critical patent/MX382765B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto terapéutico para la prevención y el tratamiento de la colangitis biliar primaria (PBC). De manera específica, la presente invención proporciona una composición farmacéutica que comprende un compuesto de la Formula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de la PBC. (Ver Fórmula).The present invention provides a therapeutic compound for the prevention and treatment of primary biliary cholangitis (PBC). Specifically, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC. (See Formula).

MX2019006721A 2016-12-09 2017-12-08 TREATMENT FOR PRIMARY BILIARY CHOLANGITIS. MX382765B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621042122 2016-12-09
PCT/IB2017/057746 WO2018104916A1 (en) 2016-12-09 2017-12-08 Treatment for primary biliary cholangitis

Publications (2)

Publication Number Publication Date
MX2019006721A true MX2019006721A (en) 2019-10-30
MX382765B MX382765B (en) 2025-03-13

Family

ID=60957351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006721A MX382765B (en) 2016-12-09 2017-12-08 TREATMENT FOR PRIMARY BILIARY CHOLANGITIS.

Country Status (8)

Country Link
US (7) US20180243263A1 (en)
EP (1) EP3551180B1 (en)
JP (1) JP6840853B2 (en)
BR (1) BR112019011740A2 (en)
ES (1) ES2894261T3 (en)
MX (1) MX382765B (en)
WO (1) WO2018104916A1 (en)
ZA (1) ZA201903649B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
BR112019010249A2 (en) 2016-11-21 2019-09-10 Viking Therapeutics Inc glycogen storage disease treatment method
MX382765B (en) * 2016-12-09 2025-03-13 Zydus Lifesciences Ltd TREATMENT FOR PRIMARY BILIARY CHOLANGITIS.
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN110934866B (en) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 Use of sitagliptin carboxylic acids and related compounds
WO2020117962A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2022040110A2 (en) * 2020-08-18 2022-02-24 Sheng Liu Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases
WO2022180612A1 (en) * 2021-02-26 2022-09-01 Cadila Healthcare Limited Orodispersible formulation of hypolipidemic agent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (en) 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR950702545A (en) 1992-07-03 1995-07-29 데이빗 로버츠 Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
ES2164241T3 (en) 1995-04-28 2002-02-16 Daiichi Seiyaku Co PENTACICLIC COMPOUNDS.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1208326C (en) 1998-04-23 2005-06-29 雷迪实验室有限公司 Heterocyclic compound and its application in medicine, its preparation method and pharmaceutical composition containing them
CN100357281C (en) 1998-05-27 2007-12-26 雷迪实验室有限公司 Bicyclic compounds, process for their preparation and pharmaceutical composition containing them
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
CZ304346B6 (en) 2000-01-19 2014-03-19 Cadila Healthcare Ltd. Substituted pyrrole derivative exhibiting hypolipidemic and hypocholesteremic activity , process for its preparation and pharmaceutical composition containing thereof
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (en) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. Cataphoresis apparatus, cataphoresis method, and detection method for organism-related material using the apparatus and the method
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
BR112012012815B8 (en) 2009-11-26 2021-05-25 Genfit use of a compound selected from 1-[4-methyl-thio-phenyl]-3-[3,5-dimethyl-4-carboxy-dimethyl-methyloxy-phenyl]prop-2-en-1-one and 2-acid [2,6-dimethyl-4-[3-[4-(methyl-thio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic
DE102010012223A1 (en) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmaceutical preparation, useful for the treatment of autoimmune disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Crohn's disease or ulcerative colitis, comprises 12-imidazolyl-1-dodecanol
WO2012051333A1 (en) 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
KR101733414B1 (en) 2011-01-31 2017-05-10 카딜라 핼쓰캐어 리미티드 Treatment for lipodystrophy
SG10201702654VA (en) 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
US20150132289A1 (en) 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
CN111228278A (en) * 2012-06-19 2020-06-05 英特塞普特医药品公司 Preparation, use and solid forms of obeticholic acid
WO2014174524A1 (en) * 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015016403A (en) 2013-05-30 2016-04-11 Cadila Healthcare Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities.
TW201636015A (en) 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
IN2013MU02470A (en) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
MX371021B (en) 2013-08-29 2020-01-13 Cadila Healthcare Ltd Polymorphic form of pyrrole derivative and intermediate thereof.
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
AU2016215179B2 (en) 2015-02-06 2021-02-25 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
MX2017012319A (en) * 2015-03-26 2018-05-11 T3D Therapeutics Inc Methods of treating liver disease using indane acetic acid derivatives.
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017064635A2 (en) * 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
MX382765B (en) * 2016-12-09 2025-03-13 Zydus Lifesciences Ltd TREATMENT FOR PRIMARY BILIARY CHOLANGITIS.

Also Published As

Publication number Publication date
WO2018104916A1 (en) 2018-06-14
US20210085644A1 (en) 2021-03-25
US20220062231A1 (en) 2022-03-03
BR112019011740A2 (en) 2019-10-29
US20230255932A1 (en) 2023-08-17
US20230201162A1 (en) 2023-06-29
US20180243263A1 (en) 2018-08-30
US20250041269A1 (en) 2025-02-06
US11872209B2 (en) 2024-01-16
EP3551180B1 (en) 2021-09-29
US20210128525A1 (en) 2021-05-06
US11433050B2 (en) 2022-09-06
JP6840853B2 (en) 2021-03-10
ZA201903649B (en) 2021-01-27
JP2020502095A (en) 2020-01-23
EP3551180A1 (en) 2019-10-16
MX382765B (en) 2025-03-13
US12178799B2 (en) 2024-12-31
ES2894261T3 (en) 2022-02-14

Similar Documents

Publication Publication Date Title
MX2019006721A (en) TREATMENT FOR PRIMARY BILE CHOLANGITIS.
CL2021001292A1 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CO2019015090A2 (en) Treatment methods for cystic fibrosis
DOP2019000201A (en) HIV INHIBITING COMPOUNDS
CY1123810T1 (en) TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS KALLIKREIN INHIBITORS IN HUMAN PLASMA
MX2024004439A (en) Therapeutic agents for neurodegenerative diseases
MX2019001581A (en) AMINOPYRIMIDINE SSAO INHIBITORS.
MX2017009449A (en) JAK INHIBITOR.
HN2012000023A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
MX2016001400A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
CR20160537A (en) 3-QUINASA DELTA PHOSFOINOSYTI INHIBITOR FOR MEDICAL USE
MX2016015434A (en) Pharmaceutical combinations for treating cancer.
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
CR20190361A (en) Therapeutic dendrimers
CY1124907T1 (en) KALLIKREIN INHIBITORS IN HUMAN PLASMA
SV2016005313A (en) CARBOXAMIDE DERIVATIVES
MX2016015437A (en) COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101.
MX392470B (en) PHARMACEUTICAL COMPOSITION COMPRISING A WT1 PEPTIDE FOR THE TREATMENT OR PREVENTION OF AN ANGIOGENIC DISEASE.
UY36123A (en) CARBOXAMIDE DERIVATIVES
UY36331A (en) SOLID PHARMACEUTICAL COMPOSITION INCLUDING AMLODIPINA AND LOSARTÁN
MX2017003140A (en) TREATMENT OF SYMPTOMS ASSOCIATED WITH ANDROGEN PRIVACY THERAPY.
AR109209A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES
CL2019001046A1 (en) Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
CU20160170A7 (en) CARBOXAMIDE DERIVATIVES